Edwards Lifesciences Corp
corporate_fare Company Profile
Edwards Lifesciences Corp (NYSE:EW) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for EW at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 13 rated 8 or above. Recent SEC coverage for EW spans 8-K, 10-Q, DEF 14A.
Recent high-impact activity:
- CMS Finalizes TAVR Coverage Rules as Edwards Adds PASCAL Ace, EVOQUE Approvals
- Edwards Q3 Sales Up 10.5% to $1.72B; Full-Year Guidance Raised Across TAVR, TMTT and EPS
- Edwards Beats on 11.2% Growth, Raises Full-Year Sales and EPS Guidance
- PASCAL Beats Medical Therapy in Tricuspid Repair Trial, 80% Cut to Moderate-or-Less TR
- PROGRESS Trial: TAVR Cuts Death/Heart Failure Risk 33% in Moderate Aortic Stenosis
Financial Snapshot
Short Interest & Short Volume
2.80 days to coverFINRA reported short interest of 9,382,239 shares in EW as of the October 30, 2026 settlement, a 0.5% increase from the prior period — about 2.8 days to cover at its recent average daily volume. On November 19, 2026, 31.8% of EW volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.